De Novo Pyrimidine Synthesis is a Targetable Vulnerability in IDH Mutant Glioma
D. D. Shi, M. R. Savani, M. M. Levitt, A. C. Wang, J. E. Endress, C. E. Bird, J. Buehler, S. A. Stopka, M. S. Regan, Y.-F. Lin, W. Gao, J. Khanal, M. Xu, B. Huang, R. B. Jennings, , McBray
This study identifies de novo pyrimidine synthesis as a therapeutic target in IDH mutant gliomas, showing that DHODH inhibitors are effective in preclinical models.
bioRxiv · Nov 30, 2021Cancer Biology